Owners, management and financials
CVR: 44860627
Secondary names: TUSTAR ApS
DKK -961,543
Gross profit
Net result: DKK -880,765
Afyx Capital ApS (33,33-49,99%), Hannibal Innovation ApS (66,66-89,99%)
CVR · view owners
Hamed Mozaffari Brodersen
Board: Karin Absalonsen (chair) and 3 members
CVR · view management
Active
Founded 29 May 2024
CVR · view overview
0 employees
Annual report 2025 · average
Name registered: BARKA Therapeutics ApS
CVR · 29/05/2024
View the full event history
BARKA Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hamed Mozaffari Brodersen. The board consists of Karin Absalonsen (chair), Claus Juan Møller-San Pedro, Hamed Mozaffari Brodersen and Ole Baadsgaard. The company is owned by Afyx Capital ApS and Hannibal Innovation ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -961,543 and a net result of DKK -880,765. Equity in the 2025 report amounted to DKK -605,209.
Selskabets formål er at drive forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler, og dermed beslægtet virksomhed efter ledelsens skøn
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 0 | -881K | 838K | -605K | 0 |
Compared to 1.038 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of BARKA Therapeutics ApS is 44860627.
BARKA Therapeutics ApS is owned by Afyx Capital ApS and Hannibal Innovation ApS.
The management of BARKA Therapeutics ApS consists of Hamed Mozaffari Brodersen.
The board of BARKA Therapeutics ApS consists of Karin Absalonsen, Claus Juan Møller-San Pedro and Hamed Mozaffari Brodersen, with Karin Absalonsen as chair.
In 2025, BARKA Therapeutics ApS reported a gross profit of DKK -961,543.
BARKA Therapeutics ApS had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
BARKA Therapeutics ApS has published its annual report for 2025. Revenue came to DKK 0, and the net result was DKK -880,765.
BARKA Therapeutics ApS has published its interim report for the period May 29, 2024 to December 31, 2024.
As of May 29, 2024, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of BARKA Therapeutics ApS.
As of May 29, 2024, Ole Baadsgaard has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Karin Absalonsen has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Claus Juan Møller-San Pedro has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Hamed Mozaffari Brodersen has joined the board of directors of BARKA Therapeutics ApS.
As of May 29, 2024, Hamed Mozaffari Brodersen is registered as director of BARKA Therapeutics ApS.
As of May 29, 2024, Afyx Capital ApS is registered as an owner of BARKA Therapeutics ApS with an ownership share of 33%.
As of May 29, 2024, Hannibal Innovation ApS is registered as an owner of BARKA Therapeutics ApS with an ownership share of 66%.
BARKA Therapeutics ApS was founded on May 29, 2024.
Companies in the same industry and area
CVR 35388737
CVR 46802683
CVR 26206308
CVR 37053678
CVR 37726028
